Delcath(DCTH) - 2024 Q3 - Quarterly Results

Revenue Expectations - For the quarter ended September 30, 2024, Delcath expects revenue of approximately $11.2 million[4] - Revenue generated from the commercialization of HEPZATO KIT in the United States is expected to be $10.0 million[4] - The announcement of $10.0 million in U.S. quarterly revenue triggers the exercise of Tranche B warrants from the March 29, 2023 PIPE[4] Warrants Exercise - Holders of the Tranche B warrants have 21 days to exercise their warrants at an effective price of $6.00 per share, totaling an aggregate exercise price of up to approximately $25 million[4] Financial Reporting - Delcath has not yet completed the preparation of its financial statements for Q3 2024, and final results may differ from preliminary estimates[5]